Diamyd Medical brings Dr Karin Hehenberger to its Board

Karin Hehenberger, MD, PhD, will join the Board of Direcors of  Diamyd Medical as affiliated member, and be proposed for election to the Board at its next General Meeting of Shareholders. Dr Hehenberger has a vast experience from both medical and financial executive positions within the fields of diabetes and other chronic diseases.

“We are proud to announce the reinforcement of our Board with Dr Hehenberger, says Erik Nerpin, Chairman of Diamyd Medical. “ Her medical and financial expertise will be of great importance for the further progress of the company” .   

Dr Hehenberger has more than 20 years of experience in the life sciences sector, and is the CEO and founder of a patient empowerment platform, Lyfebulb, headquartered in NYC, USA.  She served as an executive at Eyetech Pharmaceuticals (EYET) and Coronado BioSciences (CNDO) and had strategic management roles at Johnson & Johnson (Vice President Metabolic Strategy), JDRF (Senior Vice President Strategic Alliances), and McKinsey, as well as senior partnership roles at public (Brummer & Partners) and private (Scandinavian Life Science Ventures) multibillion dollar investment funds.  She received her MD and PhD degrees from  Karolinska Institutet, and did her post-doctoral fellowship as a JDRF stipend recipient at the Joslin Diabetes Center, Harvard Medical School. Dr Hehenberger was diagnosed with Type 1 diabetes 31 years ago, and has as her personal mission to improve the outcomes for people living with diabetes.

“It is with great excitement that I join the Board of Diamyd Medical, which is currently at a critical stage of development,” says Karin Hehenberger. “The field of Type 1 diabetes has not seen a major therapeutic or preventative approach since the discovery of insulin 100 years ago, so being part of an effort that could make an impact on a whole population of people living with diabetes, as well as on those not yet diagnosed, was an opportunity that I could not pass on.”

Karin Hehenberger has acquired 10,000 B-shares in Diamyd Medical from its founder and largest shareholder, Anders Essen-Möller.

About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on April 20, 2021, 10.25 CET.


  PDF version